×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
AMGN – amgen inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
AMGN
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/22
09:26 am
amgn
Investing in Pharma Stocks? Check These 3 Things First [Yahoo! Finance]
Low
Report
Investing in Pharma Stocks? Check These 3 Things First [Yahoo! Finance]
11/20
04:00 pm
amgn
AMGEN ANNOUNCES SENIOR EXECUTIVE RESEARCH APPOINTMENT
Low
Report
AMGEN ANNOUNCES SENIOR EXECUTIVE RESEARCH APPOINTMENT
11/20
10:06 am
amgn
Ischemic Heart Disease (IHD) Drugs Strategic Research Report 2024: Market to Grow by $1.1 Billion During 2023-2030, Driven by Increasing Demand for Combination Therapies [Yahoo! Finance]
Low
Report
Ischemic Heart Disease (IHD) Drugs Strategic Research Report 2024: Market to Grow by $1.1 Billion During 2023-2030, Driven by Increasing Demand for Combination Therapies [Yahoo! Finance]
11/19
10:51 am
amgn
How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks [Yahoo! Finance]
Low
Report
How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks [Yahoo! Finance]
11/18
01:17 pm
amgn
Celltrion presents additional data from phase III randomized controlled trials to further support biosimilarity for CT-41 (biosimilar candidate of denosumab) and CT-P47 (biosimilar candidate of tocilizumab) at American College of Rheumatology (ACR) Conver
Low
Report
Celltrion presents additional data from phase III randomized controlled trials to further support biosimilarity for CT-41 (biosimilar candidate of denosumab) and CT-P47 (biosimilar candidate of tocilizumab) at American College of Rheumatology (ACR) Conver
11/18
09:56 am
amgn
Is Amgen Inc. (AMGN) the Best Immunotherapy Stock to Buy Now? [Yahoo! Finance]
Low
Report
Is Amgen Inc. (AMGN) the Best Immunotherapy Stock to Buy Now? [Yahoo! Finance]
11/15
09:00 pm
amgn
AMGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Amgen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Low
Report
AMGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Amgen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
11/15
08:04 am
amgn
Amgen Inc. (NASDAQ: AMGN) is now covered by analysts at Wolfe Research. They set a "peer perform" rating on the stock.
Medium
Report
Amgen Inc. (NASDAQ: AMGN) is now covered by analysts at Wolfe Research. They set a "peer perform" rating on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/6
07:47 pm
amgn
Form 4 AMGEN INC For: Nov 05 Filed by: Khosla Rachna
Low
Report
Form 4 AMGEN INC For: Nov 05 Filed by: Khosla Rachna
11/6
07:45 pm
amgn
Form 4 AMGEN INC For: Nov 05 Filed by: Busch Matthew C.
Low
Report
Form 4 AMGEN INC For: Nov 05 Filed by: Busch Matthew C.
11/6
07:41 pm
amgn
Form 4 AMGEN INC For: Nov 04 Filed by: ISHRAK OMAR
Low
Report
Form 4 AMGEN INC For: Nov 04 Filed by: ISHRAK OMAR
11/6
07:39 pm
amgn
Form 4 AMGEN INC For: Nov 04 Filed by: HOLLEY CHARLES M
Low
Report
Form 4 AMGEN INC For: Nov 04 Filed by: HOLLEY CHARLES M
11/6
07:38 pm
amgn
Form 4 AMGEN INC For: Nov 04 Filed by: Drake Michael V
Low
Report
Form 4 AMGEN INC For: Nov 04 Filed by: Drake Michael V
10/31
06:02 am
amgn
Form 10-Q AMGEN INC For: Sep 30
Low
Report
Form 10-Q AMGEN INC For: Sep 30
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/23
Amgen And The Amgen Foundation Commit Up To $12.5 Million To Support COVID-19 Relief Efforts
8.8%
8/8 Form 4 AMGEN INC For: Aug 07 Filed by: SUGAR RONALD D 6.2%
7/30 Amgen Reports Second Quarter 2019 Financial Results 6.1%
4/2 Amgen And Adaptive Biotechnologies Announce Strategic Partnership To Develop A Therapeutic To Prevent Or Treat COVID-19 6.0%
8/26 UPDATE 2-Amgen to buy Celgene's psoriasis drug Otezla for $13.4 bln in cash [Reuters (UK)] 5.9%
4/7 Biotech Giant Amgen Entered The Coronavirus Arena — But Is It A Buy? [Investor's Business Daily] 5.9%
3/28 Amgen Announces Positive Results At ACC.20/WCC From Phase 3B Study Of Repatha® (Evolocumab) In People Living With HIV Who Have High LDL-Cholesterol 5.2%
8/12 Amgen, Inc. (NASDAQ: AMGN) had its "positive" rating re-affirmed by analysts at Wells Fargo & Co. They now have a $202.00 price target on the stock, up previously from $197.00. 5.0%
3/13 Amgen, Inc. (NASDAQ: AMGN) was upgraded by analysts at Cfra from a "hold" rating to a "buy" rating. 4.1%
3/26 Amgen, Inc. (NASDAQ: AMGN) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $250.00 to $240.00. They now have an "outperform" rating on the stock. 3.1%
8/8 Form 4 AMGEN INC For: Aug 07 Filed by: SUGAR RONALD D 6.2%
7/30 Amgen Reports Second Quarter 2019 Financial Results 6.1%
4/2 Amgen And Adaptive Biotechnologies Announce Strategic Partnership To Develop A Therapeutic To Prevent Or Treat COVID-19 6.0%
8/26 UPDATE 2-Amgen to buy Celgene's psoriasis drug Otezla for $13.4 bln in cash [Reuters (UK)] 5.9%
4/7 Biotech Giant Amgen Entered The Coronavirus Arena — But Is It A Buy? [Investor's Business Daily] 5.9%
3/28 Amgen Announces Positive Results At ACC.20/WCC From Phase 3B Study Of Repatha® (Evolocumab) In People Living With HIV Who Have High LDL-Cholesterol 5.2%
8/12 Amgen, Inc. (NASDAQ: AMGN) had its "positive" rating re-affirmed by analysts at Wells Fargo & Co. They now have a $202.00 price target on the stock, up previously from $197.00. 5.0%
3/13 Amgen, Inc. (NASDAQ: AMGN) was upgraded by analysts at Cfra from a "hold" rating to a "buy" rating. 4.1%
3/26 Amgen, Inc. (NASDAQ: AMGN) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $250.00 to $240.00. They now have an "outperform" rating on the stock. 3.1%
TOP News Decliners
3/14
Amgen, Inc. (NASDAQ: AMGN) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating.
-6.8%
3/7 Hedge Funds Have Never Been This Bullish On NVIDIA Corporation (NVDA) [Yahoo! Finance News] -5.8%
2/27 Amgen, Inc. (NASDAQ: AMGN) is now covered by analysts at Barclays PLC. They set an "equal weight" rating on the stock. -5.1%
3/24 Form 4 AMGEN INC For: Mar 20 Filed by: REESE DAVID M -4.6%
4/30 Form 8-K AMGEN INC For: Apr 30 -4.6%
1/30 Q4/2019 12/31/2019 EPS 3.640 ZacksConsensus 3.470 ActVsEst 0.170 - Beat -4.5%
2/25 Amgen Stock Is Forming A Flat Base — Is It Time To Bet On AMGN Stock? [Investor's Business Daily] -3.8%
8/2 Form 4 AMGEN INC For: Aug 01 Filed by: Santos Esteban -3.1%
3/10 Form 4 AMGEN INC For: Mar 09 Filed by: REESE DAVID M -2.8%
3/31 Form 8-K AMGEN INC For: Mar 31 -2.8%
3/7 Hedge Funds Have Never Been This Bullish On NVIDIA Corporation (NVDA) [Yahoo! Finance News] -5.8%
2/27 Amgen, Inc. (NASDAQ: AMGN) is now covered by analysts at Barclays PLC. They set an "equal weight" rating on the stock. -5.1%
3/24 Form 4 AMGEN INC For: Mar 20 Filed by: REESE DAVID M -4.6%
4/30 Form 8-K AMGEN INC For: Apr 30 -4.6%
1/30 Q4/2019 12/31/2019 EPS 3.640 ZacksConsensus 3.470 ActVsEst 0.170 - Beat -4.5%
2/25 Amgen Stock Is Forming A Flat Base — Is It Time To Bet On AMGN Stock? [Investor's Business Daily] -3.8%
8/2 Form 4 AMGEN INC For: Aug 01 Filed by: Santos Esteban -3.1%
3/10 Form 4 AMGEN INC For: Mar 09 Filed by: REESE DAVID M -2.8%
3/31 Form 8-K AMGEN INC For: Mar 31 -2.8%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: